Treatment of canavan disease
AssigneeCity of Hope
InventorsYanhong SHI, Jianfei CHAO, Wendong LI
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods of treating Canavan disease in a subject through restoring ASPA enzymatic activities in the subject by expressing exogenous wild type ASPA gene in the brain of the subject. Also disclosed are a process of producing neural precursor cells, including NPCs, glial progenitor cells and oligodendroglial progenitor cells, which express an exogenous wild type ASPA gene and the neural precursor cells produced by this process.
Claims20
A method for treating Canavan disease in a subject, comprising:
- reprogramming or converting somatic cells isolated from the subject into induced pluripotent stem cells (iPSCs);
- obtaining ASPA neural progenitor cells (NPCs) expressing wild type or functional ASPA;
- wherein at least 90% of the ASPA NPCs are CD133 positive and SSEA4 negative;
- and
- transplanting the ASPA NPCs into the brain of the subject, wherein the ASPA NPCs are obtained by:
- differentiating the iPSCs into NPCs and introducing wild type ASPA gene into the NPCs by (i) transducing the NPCs with a lentivirus vector comprising the wild type ASPA gene, or (ii) correcting mutated ASPA gene of the NPCs by CRISPR/Cas 9 or TALEN-based gene editing.
(canceled)
9-13. (canceled)
A method of producing ASPA neural precursor cells, comprising:
- reprogramming or converting somatic cells isolated from a subject suffering from Canavan disease into induced pluripotent stem cells (iPSCs);
- and
- obtaining ASPA neural precursor cells expressing wild type or functional ASPA by conducting a genetical correction of the iPSCs before or after differentiating the iPSCs into the neural precursor cells,
- wherein the ASPA neural precursor cells are obtained by:
- introducing wild type or functional ASPA gene in the iPSCs to obtain genetically corrected iPSCs which express wild type or functional ASPA,
- wherein at least 90% of the ASPA NPCs are CD133 positive and SSEA4 negative;
- and
- differentiating the genetically corrected iPSCs into neural precursor cells or differentiating the iPSCs into neural precursor cells;
- and introducing wild type or function ASPA gene into the neural precursor cells.
21-27. (canceled)
A method for treating Canavan disease in a subject, comprising:
- (a) the population comprising NPCs that are:
- (i) derived from differentiated iPSCs that are in turn derived from reprogrammed or converted somatic cells isolated from the subject, and
- (ii) genetically corrected to express a wild type or functional ASPA gene by:
- transducing the NPCs with a lentivirus vector comprising the wild type or functional ASPA gene, or
- correcting mutated ASPA gene of the NPCs by CRISPR/Cas 9 or TALEN-based gene editing;
- (iii) at least 90% CD133 positive and SSEA4 negative;
- and
- (b) transplanting, into the brain of the subject, the population of ASPA NPCs.
Dependencies are inferred from the claim text.